Accession NumberDB01370  (DB11314)
TypeSmall Molecule

A metallic element that has the atomic number 13, atomic symbol Al, and atomic weight 26.98.

Aluminium atom
External IDs C.I. 77000 / CI 77000 / E-173 / INS NO.173 / INS-173
Product Ingredients
IngredientUNIICASInChI KeyDetails
Aluminium phosphateF92V3S521O 7784-30-7ILRRQNADMUWWFW-UHFFFAOYSA-KDetails
Aluminum acetate80EHD8I43D 139-12-8WCOATMADISNSBV-UHFFFAOYSA-KDetails
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
AstringentGel.008 mg/4mLTopicalCa Botana International2015-01-01Not applicableUs
Domeboro CoolingGel5 mg/mLTopicalMOBERG PHARMA NORTH AMERICA LLC2016-03-01Not applicableUs
GelfosGel61.9 g/100gOralBoryung Pharmaceutical Co., Ltd2015-04-182016-12-13Us
Gelfos MGel61.9 g/100gOralBoryung Pharmaceutical Co., Ltd2015-04-182016-12-13Us
Gelfos MGel61.9 g/100gOralBoryung Pharmaceutical Co., Ltd2016-02-282016-04-05Us
GelfoseGel61.9 g/100gOralBoryung Pharmaceutical Co., Ltd2015-03-082016-12-13Us
Gelfose MGel61.9 g/100gOralBoryung Pharmaceutical Co., Ltd2015-03-082016-12-13Us
Humco Aluminum Acetate (burrow)Liquid530 mg/mLTopicalHumco Holding Group. Inc.1998-03-25Not applicableUs
Pedi-boro Soak PaksPowder, for solution615 mg/1TopicalPedinol Pharmacal, Inc.2013-01-15Not applicableUs
Tricalm Extra StrengthSolution3 mg/mLTopicalCosmederm Bioscience2015-03-01Not applicableUs
Tricalm HydrogelGel2 mg/mLTopicalCosmederm Bioscience2013-11-01Not applicableUs
Zo Medical Surfatrol AstringentPowder4866 mg/4.866gTopicalZo Skin Health Inc2016-08-01Not applicableUs
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixtures
Buro-sol Otic SolutionGlaxosmithkline Inc
Gelfos MBoryung Pharmaceutical Co., Ltd
Oti-solJamp Pharma Corporation
Star-otic SolutionStellar Pharmacal Corp
CAS number7429-90-5
WeightAverage: 26.9815
Monoisotopic: 26.981538441
Chemical FormulaAl
IndicationNot Available
Structured Indications Not Available
PharmacodynamicsNot Available
Mechanism of action

Aluminum Acetate is an astringent. An astrignent is a chemical that tends to shrink or constrict body tissues, usually locally after topical medicinal application. The shrinkage or constriction is through osmotic flow of water (or other fluids) away from the area where the astringent was applied. Astringent medicines cause shrinkage of mucous membranes or exposed tissues and are often used internally to check discharge of blood serum or mucous secretions. This can happen with a sore throat, hemorrhages, diarrhea, or with peptic ulcers. Externally applied astringents, which cause mild coagulation of skin proteins, dry, harden, and protect the skin. Acne sufferers are often advised to use astringents if they have oily skin. Astringents also help heal stretch marks and other scars. Mild astringent solutions are used in the relief of such minor skin irritations as those resulting from superficial cuts, allergies, insect bites, or fungal infections such as athlete's foot.

TargetKindPharmacological actionActionsOrganismUniProt ID
SerotransferrinProteinunknownNot AvailableHumanP02787 details
Sodium/potassium-transporting ATPase subunit alpha-1Proteinunknown
HumanP05023 details
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organismsNot Available
PathwaysNot Available
Pharmacogenomic Effects/ADRs Not Available
Drug Interactions Not Available
Food InteractionsNot Available
Synthesis Reference

Bela Czegledi, Mihaly Csovari, Miklos Erdelyi, Lajos Streker, Istvan Toth, Katalin Szabo nee Mogyorosi, Szilard Riederauer, Geza Szentgyorgyi, "Process for producing alumina and ferric oxide from aluminium carriers with high iron and silicon content." U.S. Patent US4366129, issued 1876.

General ReferencesNot Available
External Links
ATC CodesA02AB03
AHFS Codes
  • 20:12.12
  • 34:00.00
  • 52:28.00
  • 56:04.00
  • 84:04.92
  • 84:12.00
  • 84:92.00
  • 88:29.00*
  • 92:02.00*
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Clinical Trials
Clinical Trials
1Active Not RecruitingPreventionCondylomata Acuminata1
1CompletedPreventionPlasmodium Falciparum Malaria1
2CompletedPreventionProphylaxis against postoperative nausea and vomiting1
2Not Yet RecruitingTreatmentMalaria caused by plasmodium vivax1
2Unknown StatusDiagnosticDermatitis, Contact1
3CompletedPreventionPlasmodium Infections1
3CompletedTreatmentFevers / Plasmodium Infections1
3CompletedTreatmentMalaria in Pregnancy1
3TerminatedTreatmentRadiation-induced Oesophagitis1
4CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Malaria caused by Plasmodium falciparum1
4CompletedTreatmentMalaria caused by Plasmodium falciparum1
4CompletedTreatmentPlasmodium Infections1
4TerminatedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Plasmodium Infections1
4Unknown StatusTreatmentUncomplicated Falciparum Malaria1
Not AvailableCompletedTreatmentPlasmodium Infections1
ManufacturersNot Available
PackagersNot Available
Dosage forms
GelTopical.008 mg/4mL
SolutionAuricular (otic)
GelTopical5 mg/mL
GelOral61.9 g/100g
LiquidTopical530 mg/mL
Powder, for solutionTopical615 mg/1
SolutionTopical3 mg/mL
GelTopical2 mg/mL
PowderTopical4866 mg/4.866g
PricesNot Available
PatentsNot Available
Experimental Properties
melting point (°C)2.375 g·cm −3Not Available
Predicted Properties
Physiological Charge0ChemAxon
Hydrogen Acceptor Count0ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area0 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity0 m3·mol-1ChemAxon
Polarizability1.78 Å3ChemAxon
Number of Rings0ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Human Intestinal Absorption+0.9838
Blood Brain Barrier+0.9733
Caco-2 permeable+0.7354
P-glycoprotein substrateNon-substrate0.881
P-glycoprotein inhibitor INon-inhibitor0.9787
P-glycoprotein inhibitor IINon-inhibitor0.9858
Renal organic cation transporterNon-inhibitor0.9108
CYP450 2C9 substrateNon-substrate0.8305
CYP450 2D6 substrateNon-substrate0.8255
CYP450 3A4 substrateNon-substrate0.8145
CYP450 1A2 substrateNon-inhibitor0.8813
CYP450 2C9 inhibitorNon-inhibitor0.9392
CYP450 2D6 inhibitorNon-inhibitor0.9716
CYP450 2C19 inhibitorNon-inhibitor0.9571
CYP450 3A4 inhibitorNon-inhibitor0.9855
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.882
Ames testNon AMES toxic0.9633
CarcinogenicityCarcinogens 0.664
BiodegradationReady biodegradable0.7326
Rat acute toxicity2.0135 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9547
hERG inhibition (predictor II)Non-inhibitor0.9746
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Mass Spec (NIST)Not Available
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
DescriptionThis compound belongs to the class of chemical entities known as homogeneous post-transition metal compounds. These are inorganic compounds containing only metal atoms,with the largest atom being a post-transition metal atom.
KingdomChemical entities
Super ClassInorganic compounds
ClassHomogeneous metal compounds
Sub ClassHomogeneous post-transition metal compounds
Direct ParentHomogeneous post-transition metal compounds
Alternative ParentsNot Available
SubstituentsHomogeneous post-transition metal
Molecular FrameworkNot Available
External Descriptorselemental aluminium (CHEBI:33629 )


Pharmacological action
General Function:
Transferrin receptor binding
Specific Function:
Transferrins are iron binding transport proteins which can bind two Fe(3+) ions in association with the binding of an anion, usually bicarbonate. It is responsible for the transport of iron from sites of absorption and heme degradation to those of storage and utilization. Serum transferrin may also have a further role in stimulating cell proliferation.
Gene Name:
Uniprot ID:
Molecular Weight:
77063.195 Da
  1. Nolte E, Beck E, Winklhofer C, Steinhausen C: Compartmental model for aluminium biokinetics. Hum Exp Toxicol. 2001 Feb;20(2):111-7. [PubMed:11327511 ]
  2. Nagaoka MH, Maitani T: Binding affinity of aluminium to human serum transferrin and effects of carbohydrate chain modification as studied by HPLC/high-resolution ICP-MS--speciation of aluminium in human serum. J Inorg Biochem. 2005 Sep;99(9):1887-94. [PubMed:16139893 ]
  3. Mizutani K, Mikami B, Aibara S, Hirose M: Structure of aluminium-bound ovotransferrin at 2.15 Angstroms resolution. Acta Crystallogr D Biol Crystallogr. 2005 Dec;61(Pt 12):1636-42. Epub 2005 Nov 19. [PubMed:16301797 ]
  4. Beardmore J, Rugg G, Exley C: A systems biology approach to the blood-aluminium problem: the application and testing of a computational model. J Inorg Biochem. 2007 Sep;101(9):1187-91. Epub 2007 Jun 12. [PubMed:17629565 ]
Pharmacological action
General Function:
Steroid hormone binding
Specific Function:
This is the catalytic component of the active enzyme, which catalyzes the hydrolysis of ATP coupled with the exchange of sodium and potassium ions across the plasma membrane. This action creates the electrochemical gradient of sodium and potassium ions, providing the energy for active transport of various nutrients.
Gene Name:
Uniprot ID:
Molecular Weight:
112895.01 Da
  1. Menz RI, Walker JE, Leslie AG: Structure of bovine mitochondrial F(1)-ATPase with nucleotide bound to all three catalytic sites: implications for the mechanism of rotary catalysis. Cell. 2001 Aug 10;106(3):331-41. [PubMed:11509182 ]
  2. Silva VS, Goncalves PP: The inhibitory effect of aluminium on the (Na+/K+)ATPase activity of rat brain cortex synaptosomes. J Inorg Biochem. 2003 Sep 15;97(1):143-50. [PubMed:14507470 ]
  3. Amador FC, Santos MS, Oliveira CR: Lipid peroxidation and aluminium effects on the cholinergic system in nerve terminals. Neurotox Res. 2001 Jul;3(3):223-33. [PubMed:15111247 ]
  4. Kohila T, Parkkonen E, Tahti H: Evaluation of the effects of aluminium, ethanol and their combination on rat brain synaptosomal integral proteins in vitro and after 90-day oral exposure. Arch Toxicol. 2004 May;78(5):276-82. [PubMed:15254985 ]
  5. Kohila T, Tahti H: Effects of aluminium and lead on ATPase activity of knockout +/- mouse cerebral synaptosomes in vitro. Altern Lab Anim. 2004 Oct;32(4):361-7. [PubMed:15651920 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Drug created on July 06, 2007 14:27 / Updated on June 11, 2017 15:50